Aktie A2PHG6 MILESTONE PHARMACEUTICALS INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Milestone Pharmaceuticals Inc.

Aktien

A2PHG6

CA59935V1076

MIST

Markt geschlossen - Nasdaq
Andere Börsenplätze
 22:00:00 28.05.2024 		% 5 Tage % 1. Jan.
1,65 USD -3,51 % Intraday Chart für Milestone Pharmaceuticals Inc. -4,07 % -1,20 %
13.05. Milestone Pharmaceuticals Inc. meldet Ergebnis für das erste Quartal bis zum 31. März 2024 CI
08.04. Milestone Pharmaceuticals kündigt Daten zu Etripamil an, die zeigen, dass Patienten? Fähigkeit der Patienten, wiederkehrende PSVT selbst zu behandeln, auf der Jahrestagung des American College of Cardiology vorgestellt CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!
100% kostenlose Registrierung
Certain Pre-Funded Warrants of Milestone Pharmaceuticals Inc. are subject to a Lock-Up Agreement Ending on 29-MAY-2024.
Certain Options of Milestone Pharmaceuticals Inc. are subject to a Lock-Up Agreement Ending on 29-MAY-2024.
Certain Common Shares of Milestone Pharmaceuticals Inc. are subject to a Lock-Up Agreement Ending on 29-MAY-2024.
Milestone Pharmaceuticals Partners with Arrhythmia Alliance on SVT Awareness
Milestone Pharmaceuticals: Q1 Earnings Snapshot
Milestone Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Regulatory and Corporate Update
Milestone Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Milestone Pharmaceuticals : Corporate Presentation
Milestone® Pharmaceuticals Announces Data Presentations on Etripamil at Heart Rhythm 2024, 2024 Stanford BioDesign Arrhythmia Technologies Retreat, and ISPOR 2024
Milestone® Pharmaceuticals to Present Data on Etripamil at the Preventative Cardiovascular Nursing Symposium
Milestone® Pharmaceuticals Announces Etripamil Data Demonstrating Patients’ Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual Meeting
Milestone Pharmaceuticals Announces Etripamil Data Demonstrating Patients? Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual Meeting
Milestone® Pharmaceuticals to Present at the 23rd Annual Needham Healthcare Conference
Milestone® Pharmaceuticals to Present Data on Etripamil at the American College of Cardiology and European Heart Rhythm Association Annual Conferences
Milestone Pharmaceuticals Resubmits Etripamil New Drug Application to FDA
Milestone Pharmaceuticals : Corporate Presentation
Milestone Pharmaceuticals Announces Resubmission of New Drug Application for Etripamil for Treatment in Paroxysmal Supraventricular Tachycardia
Milestone Pharmaceuticals Inc. Announces Resubmission of New Drug Application for Etripamil for Treatment in Paroxysmal Supraventricular Tachycardia
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Regulatory and Corporate Update
Milestone Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A2PHG6 Aktie
  4. Nachrichten Milestone Pharmaceuticals Inc.
  5. Andere Sprachen